OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:06 2024-04-23 pm EDT			5-day change	1st Jan Change
1.245 ^USD	+1.22%		+2.89%	-17.55%

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

OPKO Health to Participate in Three Upcoming Investment Conferences

November 11, 2020 at 09:10 am EST

MIAMI, Nov. 11, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.

H.C. Wainwright 6^th Annual Israel Virtual Conference, November 12, 2020. Management will participate in a fireside chat on Thursday, November 12^th at 9:00 a.m. ET and will be available for one-on-one meetings.
Jefferies 2020 Virtual London Healthcare Conference, November 17-19, 2020. Management will deliver a company presentation on Wednesday, November 18^th at 10:15 a.m. ET and will be available for one-on-one meetings. A live and archived webcast of the presentation will be available in the Investors section of OPKO’s website here.
Piper Sandler 32^nd Annual Virtual Healthcare Conference, December 1-3, 2020. Management will participate in a fireside chat and will be available for one-on-one meetings. A replay of the fireside chat will be available in the Investors section of OPKO’s website here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Latest news about OPKO Health, Inc.

Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	Mar. 14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	Mar. 13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	Mar. 12	MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	Feb. 28	MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	Feb. 27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing	Feb. 21	MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors	Feb. 20	CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board	Feb. 09	CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform	Feb. 05	MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing	Jan. 19	MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing	Jan. 18	MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing	Jan. 16	MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing	Jan. 11	MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029	Jan. 09	MT
Opko Health Insider Bought Shares Worth $1,344,600, According to a Recent SEC Filing	Jan. 08	MT
Opko Health Insider Bought Shares Worth $514,093, According to a Recent SEC Filing	Jan. 05	MT
OPKO Health Prices $200 Million Convertible Senior Notes Offering	Jan. 05	MT
Top Midday Decliners	Jan. 04	MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	Jan. 04	MT

Chart OPKO Health, Inc.

Duration

Period

More charts

Company Profile

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Sector

Healthcare Facilities & Services

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OPKO Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.25 USD

Average target price

4.25 USD

Spread / Average Target

+240.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
OPKO HEALTH, INC.	-17.55%	871M
SONIC HEALTHCARE LIMITED	-15.90%	8.36B
RADNET, INC.	+40.44%	3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-29.20%	2.87B
SYNLAB AG	-7.88%	2.47B
DR. LAL PATHLABS LIMITED	-12.25%	2.24B
FLEURY S.A.	-18.40%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.52%	1.23B
METROPOLIS HEALTHCARE LIMITED	+9.05%	1.13B
ADICON HOLDINGS LIMITED	-16.41%	1.04B

Medical & Diagnostic Laboratories